Home Belviq Lawsuits

Belviq Lawsuits

Belviq lawsuits are legal claims against Eisai Inc., the drug’s manufacturer, filed by people who took Belviq long-term and were diagnosed with cancer. Belviq cancer lawsuits claim Eisai Inc. failed to warn of the risk of taking the drug long-term. Belviq was withdrawn from the market in 2020.

This is an active lawsuit

See If You Qualify for a Belviq Lawsuit

If you or your loved one were diagnosed with cancer after taking Belviq, you may be entitled to compensation. Get a free case review today.

  • A+BBB Rating
  • 4.9 StarGoogle Reviews

We value your privacy. By clicking REVIEW MY CASE, you agree to our privacy policy and disclaimer. After submitting, you will be contacted by one or more of Drugwatch's trusted legal partners (including autodialed and prerecorded calls or text/SMS messages). Msg. and data rates apply. Your consent to text messaging is not required for a case review and you may opt out of text messages at any time by texting STOP. This is legal advertising.

  • A+BBB Rating
  • 4.9 StarGoogle Reviews
Last Modified: March 2, 2024
Fact Checked

Editors carefully fact-check all Drugwatch.com content for accuracy and quality.

Drugwatch.com has a stringent fact-checking process. It starts with our strict sourcing guidelines.

We only gather information from credible sources. This includes peer-reviewed medical journals, reputable media outlets, government reports, court records and interviews with qualified experts.

Why Trust DrugWatch?

Drugwatch.com has been empowering patients for more than a decade

Drugwatch.com has provided reliable, trusted information about medications, medical devices and general health since 2008. We’ve also connected thousands of people injured by drugs and medical devices with top-ranked national law firms to take action against negligent corporations.

Our team includes experienced medical writers, award-winning journalists, researchers and certified medical and legal experts. Drugwatch.com is HONCode (Health On the Net Foundation) certified. This means the high-quality information we provide comes from credible sources, such as peer-reviewed medical journals and expert interviews.

The information on Drugwatch.com has been medically and legally reviewed by more than 30 expert contributors, including doctors, pharmacists, lawyers, patient advocates and other health care professionals. Our writers are members of professional associations, including American Medical Writers Association, American Bar Association, The Alliance of Professional Health Advocates and International Society for Medical Publication Professionals.

About Drugwatch.com

  • Assisting patients and their families since 2008.
  • Helped more than 12,000 people find legal help.
  • A+ rating from the Better Business Bureau.
  • 5-star reviewed medical and legal information site.
Learn More About Us


"Drugwatch opened my eyes to the realities of big pharmacy. Having a family member with major depression and anxiety, I was looking for information on her medications. I found information that was very helpful, that her psychiatrist never told her."
Marianne Zahren Patient’s Family Member
  • Google Business Rating
  • BBB A+ Rating Logo

Recent Belviq Lawsuit Updates

Belviq lawsuits haven’t been grouped into multidistrict litigation. Litigation in these cases has been stayed since 2022 to try and settle claims, and there have been no trials scheduled.

Status of Belviq Lawsuits

  • March 2024: There aren’t any known active lawsuits remaining in this litigation, but some attorneys continue to accept new cases.
  • December 2023: Some Belviq lawsuits have been settled while negotiations continue. Plaintiffs’ lawyers are optimistic that Eisai will soon reach a global settlement. In the meantime, lawyers are still accepting cases.
  • July 2023: Settlement negotiations for a potential global settlement continue.
  • January 2023: Some cases have settled for confidential amounts.
  • May 2022: U.S. District Judge Anne Conway agreed to a request to stay all proceedings while plaintiffs and defendants try to negotiate a global settlement.
  • August 2021: Judges ruled that Belviq lawsuits would proceed without an MDL and remain in their respective state courts.
  • April 2021: Plaintiffs’ lawyers asked the U.S. Judicial Panel on Multidistrict Litigation (JPML) to consolidate cases from across the country into multidistrict litigation (MDL) in the Eastern District of Louisiana.
  • February 2020: Esai issued a voluntary recall for Belviq and Belviq XR. The FDA found the risks of cancer outweigh the benefits of the drug.

“It is estimated that hundreds of individuals (if not numbers in the low thousands) developed cancer as a direct and proximate result of using and ingesting Defendants’ Belviq. Many of these injured individuals have filed or will be filing lawsuits against Defendants,” lawyers said in court documents.

Normally, when lawyers expect hundreds or thousands of cases against one defendant with similar injuries, the cases transfer to an MDL to conserve costs and smooth out litigation. But judges ruled that Belviq cases would not proceed to an MDL.

What Led People to File Belviq Lawsuits?

Belviq users who developed pancreatic, colorectal, and lung cancer began filing lawsuits shortly after the FDA found an increased risk of these cancers in people who took the drug. Lawsuits said Eisai Inc. failed to warn about the risk. Arena Pharmaceuticals manufactures Belviq at its facility in Switzerland. Eisai Inc. marketed and distributed Belviq in the United States. Both companies are named in lawsuits.

On Feb. 13, 2020, the FDA requested that Eisai Inc. voluntarily withdraw the drug over the potential cancer link. The agency based its decision on results from a five-year study of Belviq users that the company had conducted to make sure there were no serious cardiovascular risks associated with the drug.

“We are taking this action because we believe that the risks of lorcaserin outweigh its benefits based on our completed review of results from a randomized clinical trial assessing safety,” the FDA announcement read.

When the FDA approved Belviq, it required Eisai to conduct a long-term study into the drug’s cardiovascular effects. The study involved 12,000 people, some taking Belviq and others taking a placebo. Data from the trial showed that 7.7 percent of the people taking Belviq developed cancer, compared to 7.1 percent taking the placebo.

Types of cancer named in Belviq lawsuits:

The company complied with the FDA’s request, but it issued a statement saying that its interpretation of data from the study differed from the FDA’s.

“The company’s assessment is that Belviq and Belviq XR continue to have a positive benefit-risk profile in the patient population for which they are indicated,” the statement read.

The statement added that Eisai respected the FDA’s decision and was working with the agency to remove its drug from the market.

See if You Qualify for a Lawsuit Our Partners

Our Trusted Legal Partners

Drugwatch partners with trusted law firms to help you take legal action. After submitting the form, one of Drugwatch's partners will contact you for a free case review.

simmons hanly conroy law firm logo weitz and luxenberg logo sokolove law firm logo levin papantonio rafferty law firm logo nigh goldenberg raso and vaughn law firm logo morgan & morgan logo the ferraro law firm logo meirowitz & wasserberg law firm logo

Who Can File a Belviq Lawsuit?

People who developed lung, pancreatic or colorectal cancer after taking Belviq for a total of six months may be eligible to file a lawsuit. It does not have to be six months in a row. They should have taken Belviq within seven years of being diagnosed with cancer.

The cancers must have originated in the lung, pancreas or colon; it cannot have spread to them from other organs. Those who lost a loved one to cancer after they took Belviq should talk to a lawyer within a year and a half of his or her death.

People considering a Belviq lawsuit should have details of their personal cancer history with them when they talk to an attorney about filing a case.

Top Belviq Cancer Lawyers

When choosing a top Belviq cancer lawyer to file a lawsuit on your behalf, it’s important to choose a lawyer who has extensive experience in pharmaceutical litigation. Be sure to ask them what their experience is and if they have had success settling cases or acquiring jury verdicts in other defective drug cases. 

For example, Drugwatch partners with Belviq lawyers Morgan & Morgan. Over the past 30 years, the firm has recovered more than $15 billion for clients and has extensive experience litigating cases against large drug companies.

If you want to file a Belviq lawsuit, you should contact a Belviq cancer lawyer right away to see if you qualify. Consultations are free. There are time limits to file a claim. If the statute of limitations runs out, you could lose your chance to file a lawsuit.

Questions to Ask a Belviq Lawyer

Do I qualify to file a Belviq cancer lawsuit?

Only a licensed Belviq lawyer can tell you if you qualify to file a Belviq cancer lawsuit. Be sure to tell the attorney about your experiences with Belviq and all the side effects you had. 

What do I need to prove my case?

To prove your cancer could have been caused by Belviq, your Belviq lawyer will need medical records, receipts and other evidence to show you took the drug and were diagnosed with cancer. The lawyer will explain any evidence needed. 

How long will my case take to settle?

Pharmaceutical cases like Belviq lawsuits may take several years to settle because of the complex science and evidence needed to prove the drug could have caused cancer. Your Belviq attorney should be able to give you more information on what time frame to expect. 

What is my Belviq cancer lawsuit worth?

Estimating how much a Belviq case is worth can be difficult in the early stages of litigation. Usually, lawyers have a better idea of how much each case is worth after cases go through bellwether test trials. Based on their previous experience, however, a Belviq lawyer may be able to give you an estimate of an average case value.

Please seek the advice of a medical professional before making health care decisions.